Document:

Exhibit 10.14

 

Agreement for Services as the Executive
Chairman

 

This agreement (this
“Agreement”) is made this 7th day of February, 2014 by and among: (i) Cardax, Inc., a Delaware corporation
with its principal offices at 2800 Woodlawn Drive, Suite 129, Honolulu, HI 96822 that was formerly known as Koffee Korner, Inc.
(the “Company”); and (ii) Nicholas Mitsakos (the “Executive Chairman”).

 

WHEREAS, prior to the
date of this Agreement, the Executive Chairman provided good and valuable services to the predecessor of the Company, Cardax Pharma,
Inc., a Delaware corporation that is now a wholly owned subsidiary of the Company (“Pharma”); and

 

WHEREAS, effective
on the date of this Agreement, the Executive Chairman has been elected to the position of Chairman of the Board of Directors (the
“Board”) of the Company and will provide good and valuable services to the Company and Pharma, including services
and the executive chairman of the Board, serving on committees of the Board and continuing as the executive chairman and member
of the board of directors of Pharma;

 

NOW, THEREFORE, for
good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Company and the Executive Chairman
agree as follows:

 

1.          Services.
From and after the date of this Agreement and during the Term (as defined below) of this Agreement, the Executive Chairman shall
provide services to the Company and Pharma as the executive chairman of each entity and provide services to committees of the Board,
as from time to time reasonably determined by the Board. The Executive Chairman will also provide similar services to any other
subsidiary that may be organized by the Company. The Executive Chairman shall provide such time and attention to the performance
of his duties in such capacity as the Executive Chairman in good faith determines is required. As a member of the Board, the Executive
Chairman shall have such duties to the Company and its stockholders as required under applicable law, giving full force and effect
to provisions of the certificate of incorporation of the Company. The services provided by the Executive Chairman under this Agreement
need not be performed at the offices of the Company and may be performed at any location as determined from time to time by the
Executive Chairman.

 

    	 

    	 

    

 

2.            Compensation.
As compensation for the services provided under this Agreement, the Executive Chairman shall receive: (i) a grant of
2,762,121 stock options under the terms and conditions of the Company’s 2014 Equity Compensation Plan and the Grant
and Stock Option Agreement (collectively, the “Option Documents”), which vest as follows: (A) 50% shall
vest on the date of this Agreement; and (B) the remaining 50% shall vest in 12 months, in equal monthly installments, in
arrears; and (ii) an annual cash compensation amount equal to $240,000 (the “Annual Payment Amount”)
payable on the same dates as the Company’s normal payroll payments. The Annual Payment Amount may be increased by the
Company. The Executive Chairman is responsible for payments of all taxes on the compensation payable to him under the terms
of this Agreement other than taxes assessed by the State of Hawaii on such amounts, which such taxes shall be paid by the
Company as and when due and payable. The Company may withhold any taxes or other payroll deductions to the extent that the
Company is required to withhold such amounts under applicable law.

 

3.            Term
of Agreement. This Agreement has a one (1) year term, commencing on the date hereof, that automatically renews unless either
party notifies the other party that the then current term will not be renewed at least ninety (90) days prior to the expiration
of such current term. The initial term of this Agreement as the same may be renewed is referred to as the “Term”.

 

4.            Termination
and Severance.

 

4.1.          This
Agreement may be terminated by the Company upon notice to the Executive Chairman at any time within 30 days after the Company has
knowledge that the Executive Chairman has committed conduct constituting Cause. This Agreement may be terminated by the Executive
Chairman at any time if the Company breaches or is in default of any of its obligations under this Agreement or any other obligation
to the Executive Chairman as a member of the Board and: (i) such breach or default is not cured on or prior to five (5) business
days after the date the Executive Chairman provides notice of such breach or default; or (ii) such breach or default occurs three
or more times during any 365 day period. Any such termination by the Executive Chairman is referred to as termination for “Good
Reason”. For the purposes of this Agreement, the term “Cause” shall mean any of the following conditions
occurred, and after a determination by the Board (without participation by the Executive Chairman) that such condition occurred,
was not cured: (i) the Executive Chairman commits (A) a breach of his fiduciary duty to the Company or any of its affiliates, to
the extent such duty is owed, (B) gross negligence, or (C) willful misconduct; or (ii) the Executive Chairman violates the internal
procedures or policies of the Company in a manner which has a material adverse effect on the reputation, business of the Company
such as conduct constituting employment discrimination or sexual harassment, which, in each case, is not cured in all material
respects by the Executive Chairman within 30 days after notice thereof.

 

4.2.          In
addition to any other compensation and benefits provided by the Company to the Executive Chairman, if this Agreement is terminated
by the Company for any reason other than for Cause or the Executive Chairman terminates this Agreement for Good Reason then the
Executive Chairman shall have the right to an amount equal to the then Annual Payment Amount of the Executive Chairman which shall
be payable monthly in arrears, on or prior to ten (10) days after each month.

 

    	2

    	 

    

  

5.           Assignment.
The rights and duties of the Executive Chairman hereunder are not assignable. The Company may assign this Agreement and all rights
and obligations hereunder to any third party who becomes a successor to the Company. Upon any such assignment by the Company, the
term “Company” as used herein shall be deemed to include any such assignee of the Company, and the assignee shall have
the right to enforce all of the Company’s rights and remedies hereunder in its own name as if a party hereto in the place
and stead of the Company.

 

6.           Binding
Effect. This Agreement shall be binding upon the parties hereto and their respective successors-in-interest, heirs and personal
representatives and, to the extent permitted herein, the assigns of the Company.

 

7.           Severability.
If any provision of this Agreement or any part hereof or the application hereof to any person or circumstance shall be finally
determined by a court of competent jurisdiction or by any arbitration panel to be invalid or unenforceable to any extent, the remainder
of this Agreement, or the remainder of such provision or the application of such provision to persons or circumstances other than
those as to which it has been held invalid or unenforceable, shall not be affected thereby and each provision of this Agreement
shall remain in full force and effect to the fullest extent permitted by law. The parties also agree that if any portion of this
Agreement, or any part hereof or application hereof, to any person or circumstance shall be finally determined by a court of competent
jurisdiction or arbitration panel to be invalid or unenforceable to any extent, then such objectionable provision shall be deemed
modified to the extent necessary so as to make it valid, reasonable and enforceable including, without limitation, modification
of the restrictive covenants of Section 9 with respect to geography, time or scope of business.

 

8.           Arbitration.
Any dispute or claim arising out of or in connection with your employment with the Company will be finally settled by binding arbitration
conducted in accordance with the then-current Hawaii Uniform Arbitration Act Rules (the “Hawaii Rules”) and
pursuant to Hawaii law without reference to rules of conflicts of law or rules of statutory arbitration. The parties agree that
any arbitration will be administered by the AAA. The location of the arbitration shall be in the same city as the Company’s
headquarters at the time of the arbitration unless otherwise agreed by Company and the Executive Chairman. Except as provided by
the Hawaii Rules, arbitration shall be the sole, exclusive, and final remedy for any dispute between the Executive Chairman and
the Company. Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction hereof. Notwithstanding
the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim relief, or to compel arbitration
in accordance with this paragraph, without breach of this arbitration provision.

 

9.           Notices.

 

9.1.          Wherever
provision is made in this Agreement for the giving of any notice, such notice shall be in writing and shall be deemed to have been
duly given if mailed by first class United States mail, postage prepaid, addressed to the party entitled to receive the same or
sent by overnight courier to such party at the address specified below:

 

    	3

    	 

    

  

If to the Company:

 

Cardax, Inc.

2800 Woodlawn Drive,
Suite 129

Honolulu, Hawaii 96822

Attn: Secretary of the
Board of Directors

 

If to the Executive
Chairman:

 

to the address maintained by the
Company in its books and records as provided by the Executive Chairman.

 

or to such other address, in any such case,
as any party hereto shall have last designated by notice to each other party.

 

9.2.          All
such notices, requests and other communications will: (i) if delivered personally to the address as provided in this Section,
be deemed given upon delivery; (ii)  if delivered by overnight courier, be deemed given upon the first business day after
such notice, request or other communication is given to such courier with all charges and fees prepaid and any required signature
of the deliveree is waived; and (iii) if delivered by mail in the manner described above to the address as provided in this
Section, be deemed given upon receipt (in each case regardless of whether such notice, request or other communication is received
by any other person to whom a copy of such notice, request or other communication is to be delivered pursuant to this Section).

 

10.         Governing
Law. For purposes of construction, interpretation and enforcement, this Agreement shall be deemed to have been entered into
under the laws of the State of Hawaii and its validity, effect, performance, interpretation, construction and enforcement shall
be governed by and subject to the laws of the State of Hawaii without reference to its choice of law rules.

 

11.         Exclusive
Jurisdiction. Subject to the provisions of Section 8, all actions and proceedings arising out of, or relating to, this Agreement
shall be heard and determined in any state or federal court sitting in the county of Honolulu, Hawaii. Each of the Company and
the Executive Chairman, by execution and delivery of this Agreement: (i) expressly and irrevocably consent and submit to the personal
jurisdiction of any of such courts in any such action or proceeding; (ii) consent to the service of any complaint, summons, notice
or other process relating to any such action or proceeding by delivery thereof to such party by hand or by U.S. certified mail
without return receipt requested, delivered or addressed as set forth in Section 9 of this Agreement; and (iii) waive any claim
or defense in any such action or proceeding based on any alleged lack of personal jurisdiction, improper venue or forum non conveniens
or any similar basis.

 

    	4

    	 

    

  

12.         Interpretation.
Section titles and headings to sections herein are inserted for convenience of reference only and are not intended to be a part
of or to affect the meaning or interpretation of this Agreement.

 

13.         Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be considered an original instrument, but all of
which shall be considered one and the same agreement.

 

[Remainder of this Page is Intentionally
Blank] 

 

    	5

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed and delivered this Agreement as of the date first written above.

 

	 	THE COMPANY
	 	 	 
	 	Cardax, Inc.
	 	 	 
	 	By:	/s/ David G. Watumull
	 	 	Name:  David G. Watumull
	 	 	Title:   Chief Executive Officer

 

	 	THE EXECUTIVE CHAIRMAN	 
	 	 	 
	 	/s/ Nicholas Mitsakos	 
	 	NICHOLAS MITSAKOS, IndividuallyExhibit 10.15 

 

JOINT DEVELOPMENT AND SUPPLY AGREEMENT

 

This Agreement is effective on the 15th
day of November 2006 (the “Effective Date”) by and between

 

BASF Aktiengesellschaft, 67056 Ludwigshafen,
Germany acting also on behalf of its Affiliates (hereinafter referred to as “BASF”).

 

and

 

Cardax Pharmaceuticals, Inc., Aiea, Hawaii
96701, USA (hereinafter referred to as “Cardax”).

 

BASF and Cardax are referred to herein
individually as a “Party” and collectively as the “Parties”.

 

Whereas BASF develops, manufactures, markets
and sells high-value performance chemicals, including fine chemicals for the pharmaceutical industry;

 

Whereas Cardax is developing proprietary
pharmaceutical compounds;

 

Whereas Cardax and BASF are interested
in developing a process for the manufacture of the Product (hereinafter defined) with the intention that BASF will manufacture
the Product and Cardax will market or license human pharmaceuticals which utilize the Product as a manufacturing intermediate;

 

Whereas BASF received an inquiry from Cardax
to prepare a proposal for process development and manufacturing of 3S, 3’S-Astaxanthin. Cardax intends to use Product as
an intermediate in the manufacture of or as an active ingredient in pharmaceutical or nutraceutical products. After signature of
the Confidentiality Agreement between Cardax and BASF dated 24.05.05/01.06.05, Cardax provided laboratory information relating
to an experimental protocol for the synthesis of homochiral Product and an analytical method for the determination of the Astaxanthin
stereoisomers and intermediates;

 

Now therefore, in consideration of the
above, it is hereby agreed as follows:

 

		1.	DEFINITIONS

 

		1.1	“Affiliate” shall mean any corporation, company, partnership, joint venture and/or firm which
controls, is controlled by, or is under common control with a specified person or entity. For purposes of this definition, “control”
shall mean (a) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or
shares having the right to vote for the election of directors, and (b) in the case of non corporate entities, direct or indirect
ownership of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of such
non-corporate entities.

  

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	 

    	 

    

 

		1.2	“Carotenoid Manufacturing Competitor” shall mean a manufacturer of synthetic carotenoids.

 

		1.3	“Chemical Manufacturing Competitor” shall mean a chemical manufacturing business.

 

		1.4	“Foreground Intellectual Property Rights” mean patents, trade, secrets and other confidential
information, database rights, know-how and all other intellectual property and neighboring rights and rights of a similar or corresponding
character in any part of the world and all applications for the protection of these rights, which cover Results.

 

		1.5	“Net Nutraceutical Sales” shall mean total invoiced sales, as licensed in Section 4.4,
made by BASF or its Affiliates to third parties in any calendar year after deduction of [***].

 

		1.6	“Product” shall mean chemically synthesized 3S, 3’S-Astaxanthin with a specification
of [***].

 

		1.7	“Results” shall mean any development or modification in or to the Technology, whether
patentable or not, conceived or developed under this Agreement.

 

		1.8	“Technology” shall mean any discovery, invention, know-how, trade secret, sample of
material, report, formulation, drawing and/or other works, technical information or data, together with any and all patent rights,
relating to the manufacture of Product.

 

		2.	CARRYING OUT OF THE PROJECT

 

		2.1	The work, timing, resources, target profiles, milestones and payments for the performance of the
work under this Agreement are documented in Appendix 1 of this Agreement. BASF shall use the same diligence and professional standards
of performance consistent with those employed for BASF’s own affairs in performing the work.

 

		2.2	The Parties agree and understand that the performance of the project within the agreed deadlines
depends upon the accurate and timely allocation of necessary resources by both Parties.

 

		2.3	Cardax will advise BASF in due time if the pilot material to be supplied by BASF will be for human
clinical use and if the final synthetic step for the manufacture of Product will have to meet cGMP requirements. In the event Cardax
requests more than the final synthetic step to be performed in accordance with cGMP, the Parties will negotiate in good faith a
reasonable increase of the price for Product, corresponding to the increase in cost of production in order to meet cGMP requirements
and a reasonable margin for BASF.

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	2

    	 

    

 

		3.	CONFIDENTIAL INFORMATION

 

		3.1	All information, plans for research and development, samples, technologies, or other matters disclosed
or to be disclosed by either Party to the other in connection with this Agreement (including intermediate and final Results and
Foreground Intellectual Property Rights) will be received and held in confidence by the recipient Party and shall be subject to
the terms and conditions set forth for the exchange of Confidential Information defined in and covered by the Confidentiality Agreement
entered into by and between the Parties on 24.05.05/01.06.05, modified in that the confidentiality obligations shall stay in effect
for [***] following the expiration or termination of this Agreement, the laws of the Switzerland shall apply as specified in Section
7.1 hereof, and disputes shall be settled as specified in Section 7.2 hereof. For the avoidance of doubt, the Parties agree that
pursuant to Section 6.9 below, the royalty obligations of Section 4.4 hereof shall survive any future expiration of such confidentiality
obligations.

 

		3.2	All Confidential Information exchanged under this Agreement shall be used by the receiving Party
solely internally within its organization for the performance of the project, as defined in Appendix 1, unless otherwise agreed
by the disclosing Party, or explicitly stated otherwise in this Agreement.

 

		3.3	Cardax may provide the Confidential Information to possible investors to the Cardax, but only provided
that such investors have signed a confidentiality agreement containing essentially similar provisions of confidentiality as contemplated
herein.

 

		4.	INTELLECTUAL PROPERTY RIGHTS

 

		4.1	The Parties agree that:

 

		(a)	BASF shall have the entire and exclusive worldwide rights, title and interest in and to all Results
relating to the manufacture of the Product (“BASF’s Interests”). BASF, at its sole discretion and expense, will
have the right to prepare, file, prosecute, maintain and enforce patents and patent applications directed to BASF’s Interests.

 

		(b)	Cardax shall have the entire and exclusive worldwide rights, title and interest in and to all Results
relating to the formulation and the pre-clinical and clinical development of the Product as an intermediate in the manufacture
of or as an ingredient in human pharmaceutical compounds (“Cardax’s Pharmaceutical Interests”) or nutraceutical
compounds (“Cardax’s Nutraceutical Interests”) (collectively “Cardax’s Interests”). Cardax,
at its sole discretion and expense, will have the right to prepare, file, prosecute, maintain and enforce patents and patent applications
directed to Cardax’s Interests.

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	3

    	 

    

 

		4.2	The Parties agree that any invention shall be and become the sole property of the relevant Party,
as set out here above, which Party shall have the right to determine whether any application for a patent shall be made and shall
have the exclusive benefit throughout the world of all Foreground Intellectual Property Rights, together with the right to maintain,
assign or abandon such Foreground Intellectual Property Rights without reference to any other person. The Parties agree to execute
and do all things necessary to vest the title and interest in such Foreground Intellectual Property Rights in the relevant Party
as set out above, at the expense of said relevant Party, which shall pay the costs of the prosecution of all applications for Foreground
Intellectual Property Rights to which it becomes entitled under this Agreement.

 

The Party intending to file a
patent application shall inform the other Party of such intended filing and shall provide the other Party with an opportunity to
comment on the text of the patent application, whenever this is possible without endangering protection. Further, not later than
thirty days after the filing date, the Party filing the patent application shall furnish the other Party with a copy of the patent
application, subject to the provisions of Article 3 here above.

 

		4.3	Each Party shall keep the Results and any Foreground Intellectual Property Rights belonging to
the other Party confidential and shall not, except as provided in this Agreement, use them without the prior written consent of
the other Party or disclose it to any third party and shall treat it in accordance with the provisions of Article 3 here above.

 

		4.4	Cardax hereby grants a non-exclusive worldwide, nontransferable license to BASF to use Cardax’s
Nutraceutical Interests (but not Pharmaceutical Interests) for the purpose of development and commercialization (directly or through
a third party) of human nutraceutical compounds containing or utilizing Product and to make available to BASF the reasonable assistance
of Cardax in designing and conducting clinical studies in the United States therefor all subject to the negotiation and agreement
by the Parties of reasonable commercial terms for such license and assistance. Such license shall be subject to the following tiered
royalty structure:

 

 (a)

 

		(i)	[***]% on Net Nutraceutical Sales < $[***]

 

		(ii)	[***]% on Net Nutraceutical Sales of $[***] or more but < $[***]

 

		(iii)	[***]% on Net Nutraceutical Sales of $[***] or more but < $[***]

 

		(iv)	[***]% on Net Nutraceutical Sales of $[***] or more but < $[***]

 

		(v)	[***]% on Net Nutraceutical Sales of $[***] or above

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	4

    	 

    

 

BASF shall have the option to have the
license converted to an exclusive license, subject to the following provisions (b)- (d). BASF shall exercise the option by written
document at any time, subject to 4.4 (e) below.

 

		(b)	Tiered royalty structure

 

		(i)	[***]% on Net Nutraceutical Sales < $[***]

 

		(ii)	[***]% on Net Nutraceutical Sales of $[***] or more but < $[***]

 

		(iii)	[***]% on Net Nutraceutical Sales of $[***] or more but < $[***]

 

		(iv)	[***]% on Net Nutraceutical Sales of $[***] or more but < $[***]

 

		(v)	[***]% on Net Nutraceutical Sales of $[***] or above

 

		(c)	Commercialization obligations

 

		(i)	[***]

 

		(ii)	[***]

 

		(d)	If BASF fails the commercialization obligations, Cardax may terminate by written notice to BASF
the exclusivity of the license. In such event, the license shall become non-exclusive and the tiered royalty schedule set out in
4.4 (a) shall apply as of the date of the notice.

 

		(e)	If at any time prior to the execution of the option with respect to an exclusive license, Cardax
gives BASF written notice that Cardax desires to [***], BASF’s right to exercise the option shall [***].

 

		(f)	Any license (either non-exclusive or exclusive) granted pursuant to this agreement or contemplated
by this agreement to BASF by Cardax for Cardax’s Nutraceutical Interests shall terminate [***].

 

		4.5	[***]

 

		4.6	[***]

 

		5.	COMMERCIAL EXPLOITATION

 

		5.1	BASF agrees to supply Cardax with up to [***] kg of Product for use by Cardax in preclinical and
human clinical trials, to be supplied at the prices and on the terms and conditions set forth in Appendix 1.

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	5

    	 

    

 

		5.2	[***], BASF shall exclusively manufacture the Product for Cardax or its licensees for use as an
intermediate in the manufacture of or as an ingredient in human pharmaceutical or [***] compounds, and Cardax or its licensee shall
exclusively purchase from BASF all of its clinical trial and commercial requirements of Product for such use. The Parties agree
that the supply and purchase of Products shall further be governed by the terms outlined in Appendix 2 hereto and such further
terms as may be set out in a definitive Supply Agreement to be negotiated in good faith by the Parties and that the Parties shall,
prior to the commencement by Cardax of the first [***] of a compound which utilizes [***] as an [***] or as an [***] (the “Supply
Date”), conclude a written Supply Agreement in accordance with such terms. In case Cardax decides to transfer Cardax’s
Interests to a third party, Cardax shall procure that such third party assumes the obligations of Cardax under the Supply Agreement,
including the obligation to exclusively purchase the Product from BASF, and, subject to such assumption by the third party, BASF
shall perform its obligations under the Supply Agreement for the benefit of the third party, including the obligation to exclusively
manufacture the Product for the third party and its licensees.

 

		5.3	In consideration of the rights granted pursuant to this Agreement, except as set forth in Section
4.4 above, BASF shall not, during the term of this Agreement, [***], directly or indirectly through one or more third parties,
the [***].

 

		6.	TERM AND TERMINATION

 

		6.1	This Agreement is valid as of the date first set forth above (the “Effective Date”)
and will continue until the end of the third year thereafter. After this initial term of three years, it shall automatically be
prolonged by periods of [***] each unless terminated by either Party giving [***] written notice prior to the end of the initial
term or any prolongation term.

 

		6.2	In the event that both Parties agree that the Project is not technically or commercially viable,
this Agreement may be terminated forthwith, upon decision by the Parties to this effect.

 

		6.3	This Agreement may be terminated immediately by either Party should the other Party be in breach
of any material obligation imposed upon it by the terms of this Agreement and shall not have remedied such breach (if capable of
remedy) within [***] days of written notice to the other Party specifying the breach and requiring such remedy.

 

		6.4	This Agreement will terminate immediately should any Party to it become insolvent, shall have a
receiver appointed or the whole or any material part of its assets or shall have any order made or resolution passed for it to
be wound up (otherwise than in furtherance of a scheme for amalgamation or reconstruction details of which shall have been notified
to the other Party).

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	6

    	 

    

 

		6.5	Each Party may terminate this Agreement if any third party not being an affiliated company of the
other Party shall acquire an interest in more than fifty percent of the issued equity share capital or voting capital of the other
Party. This provision shall not apply if such an interest in Cardax is acquired by an entity that is not a Chemical Manufacturing
Competitor.

 

		6.6	BASF shall be entitled to terminate this agreement in writing without notice period if BASF in
its own discretion decides to exit the business of manufacture of Astaxanthin. However, upon request of Cardax, BASF shall make
available a stock of Product in order to cover Cardax’s requirements for a transition period, [***]. Except as provided in
Section 6.8 and in the Supply Agreement, there shall be no compensation rights of Cardax or any third party arising from such termination.

 

		6.7	Either Party may terminate this Agreement in writing without notice period if any of the milestones
listed in Appendix 1 hereto is not reached within the timeframe indicated in Appendix 1 plus [***] and the Parties could not agree
to a prolongation of such timeframes.

 

		6.8	In the event of termination of this Agreement by either Party in accordance with Sections 6.1 and
6.6, the terminating Party shall, upon request of the other Party, grant the other Party a reasonable royalty-bearing, irrevocable,
worldwide, non-exclusive license, with the right to sublicense, to use BASF’s Interests (if BASF is the terminating Party)
or Cardax’s Nutraceutical Interests (but not Cardax’s Pharmaceutical Interests) (if Cardax is the terminating Party),
including such assistance and advice as may be reasonably required to enable the other Party to exercise the rights licensed to
it; excluding, however, the license or transfer of any rights that are not part of the Foreground Intellectual Property Rights.

 

		6.9	The provisions of Sections 3, 4, 6.6, 6.8, 7 and 8 shall survive the expiry or termination of the
present Agreement.

 

		7.	LAW AND ARBITRATION

 

		7.1	This Agreement shall be governed in all respects by, and be construed and governed in accordance
with the laws of Switzerland excluding its conflicts of law principles and excluding any application of the United Nations Convention
on the International Sale of Goods.

 

		7.2	If a controversy, claim or dispute arises out of or relates to any provision of this Agreement
or the breach thereof, and including the validity of any provisions thereof, the Parties will make all efforts to find a mutually
acceptable solution. In the absence of such an agreement within [***] days after the date at which one Party has notified the other
Party that a dispute exists, the dispute shall be finally settled, ousting jurisdiction by ordinary courts, by a three-member arbitral
tribunal in accordance with the arbitration rules of the International Chamber of Commerce. The unsuccessful party shall bear the
costs of the proceedings and the costs and expenses incurred by the successful party for the proper conduct of the matter. Where
no party is completely successful, the costs of the proceedings and the costs and expenses incurred by the parties for the proper
conduct of the matter shall be shared proportionately. The seat of the arbitration shall be New York City and New York City shall
be the location where all proceedings will be conducted. The language for the proceedings shall be the English language.

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	7

    	 

    

 

		8.	GENERAL PROVISIONS

 

		8.1	Neither Party is entitled to assign, transfer, charge, encumber or otherwise deal with the whole
or any part of this Agreement or its obligations hereunder provided, however, that either Party may assign this Agreement, without
the consent of the other Party, (i) to any of its Affiliates, if the assigning Party guarantees the full performance of its Affiliates’
obligations hereunder, provided however, that the Affiliate shall be obliged to re-assign the Agreement and all rights and obligations
thereunder to Cardax once the Affiliate ceases to be an Affiliate of Cardax, or (ii) in connection with the transfer or sale of
all or substantially all of the assets or business to which this Agreement relates or in the event of its merger or consolidation
with another company, provided however, that BASF shall in such event enjoy the rights of [***] and [***] set out in Section 4.5
and 4.6 herein.

 

		8.2	Other than as specified in this Agreement or otherwise agreed in writing, nothing in this Agreement
shall imply, create, grant or transfer any license or authority in respect of any intellectual property including patents, designs,
trademarks, copyrights or confidential information or know-how. Except as specified in this Agreement nothing in this Agreement
shall be construed as providing a commitment of any kind to enter into or modify any further agreement, undertake or modify any
further obligation, accept or modify any liability or purchase any goods or services. This Agreement shall not constitute the Parties
partners or either Party the agent of the other for any purpose.

 

		8.3	Other than as specified in this Agreement, the Parties shall at all times be free to engage in
research, development and/or supply programmes and agreements with third parties relating to or encompassing their respective know-how,
information, data and/or experience.

 

		8.4	Any notices given under this Agreement shall be in writing and sent to the recipient Party’s
address as indicated at the head of this Agreement.

 

		8.5	This Agreement and any Appendix hereto, as well as the Confidentiality Agreement dated 24.05.05/01.06.05,
as expressly modified pursuant to Section 3.1, contain the entire understanding of the Parties as to the subject matter, supersedes
all prior and collateral communications, reports and understandings between the Parties relating to the subject matter and cannot
be modified except by a written document bearing the signatures of both Parties hereto.

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	8

    	 

    

 

		8.6	All communications between the Parties with respect to any of the provisions of this Agreement
will be sent to the addresses set out below, or to other addresses as designated by one Party to the other by notice pursuant hereto,
by internationally recognized courier or by prepaid certified, air mail (which shall be deemed received by the other Party on the
seventh business day following deposit in the mails), or by facsimile transmission or other electronic means of communication

 

If to BASF, at:

 

BASF Aktiengesellschaft

[***]

67117 Limburgerhof

GERMANY

 

If to Cardax at:

 

Cardax Pharmaceuticals, Inc.

David Watumull

99-193 Aiea Heights Drive Suite 400

Alea, HI 96701

 

IN WITNESS WHEREOF, the Parties have executed
this Agreement as of the date first set forth above.

 

Made in two originals in Honolulu, Hawaii
USA on October 13, 2006.

 

	Cardax Pharmaceuticals, Inc.	 	BASF Aktiengesellschaft
	 	 	 
	By:	/s/ David G. Watumull	 	By:	[***]
	 	 	 
	Title: President & CEO	 	Title:  Director               Legal Counsel

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE
BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS
ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

    	9

    	 

    

 

APPENDIX I

 

 to the

 

Joint Development and Supply Agreement

 

between BASF AG and Cardax Pharmaceuticals, Inc.

 

The following project proposal was developed
based on the Cardax information and on BASF process knowledge for racemic Astaxanthin.

 

		A.	Milestones

 

It is proposed to conduct the project in
discrete steps (Milestones). Each milestone will define clear go-no go positions; the completion of the milestones are essential
for the successful completion of the project.

 

Milestone
1.  

 

[***]

 

Upon acceptance of BASF’s proposal
by Cardax BASF will provide an updated [***] for the project.

 

Completion Date: [***] after the Effective
Date of this Agreement

 

Milestone
2.  

 

[***]

 

Completion Date: [***] weeks after Completion
of Milestone 1

 

Cost: [***] EUR, payment due within [***]
days after date of invoice from BASF

 

Milestone
3.  

 

[***]

 

Completion Date: [***] weeks, start parallel
to Milestone 1; completion after [***]

 

Cost: [***] EUR, payment due within [***]
days after date of invoice from BASF

 

Milestone
4.  

 

[***]

 

Completion Date: [***] weeks after Completion
of Milestone 3

 

    	10

    	 

    

 

Cost: [***] EUR. The first payment of [***]
EUR will be due within [***] days after BASF has announced the start of its work. After successful completion at BASF’s discretion,
the second payment of [***] EUR will be due within [***] days after date of invoice from BASF.

 

Milestone
5.  

 

[***]

 

Completion Date: Within [***] weeks after
successful completion of Milestone 4

 

Milestone
6.  

 

[***]

 

[***]kg

 

Completion Date: [***] weeks after Completion
of Milestone 5

 

Total product cost: [***] EUR; payment
due within [***] days after date of invoice from BASF

 

Or

 

[***] kg

 

Completion Date: [***] weeks after Completion
of Milestone 5

 

Total product cost: [***] EUR; payment
due within [***] days after date of invoice from BASF

 

Or

 

[***] kg

 

Completion Date: total of [***] weeks after
Completion of Milestone 5

 

Total product cost: [***] EUR; payment
due within [***] days after date of invoice from BASF

 

Additional quantities ([***] kg, [***]
weeks per [***] kg) beyond the [***] kg batch: [***] EUR/kg, to be specified as needed and dependent of appropriate timing.

 

Milestone
7.  

 

[***]

 

Duration: [***]

 

Cost: [***]

 

    	11

    	 

    

 

		B.	Progress Reports

 

Upon completion of each milestone BASF
will provide Cardax with a written progress report detailing an updated time and cost estimate for the remaining milestones based
on the experience made and ask Cardax for clearance to begin the following milestone. In case unforeseen problems occur during
elaboration of a milestone, BASF will immediately inform Cardax specifying the effect of such problems on further development and
on cost and time estimates any work requiring additional time of more than [***] to complete or additional cost of more than [***]%
shall be subject to the prior written approval of Cardax.

 

		C.	Payment

 

Payment by Cardax of the costs associated
with each milestone will be due as defined above. If the project is terminated by Cardax, Cardax will pay to BASF all costs reasonably
incurred until the date of termination.

 

    	12

    	 

    

 

APPENDIX 2

 

To the Joint Development and Supply Agreement

 

between BASF Aktiengesellschaft and Cardax Pharmaceuticals, Inc.

 

Terms of Supply of Product

 

Subject to the negotiation and execution by the Parties of a mutually acceptable

 

definitive Supply Agreement

 

A Supply Agreement between the Parties
would include, but not be limited to, the following terms:

 

A.               
[***], BASF shall exclusively supply the Product to Cardax and its licensees for use as an intermediate in the
manufacture of or an ingredient in human pharmaceutical or [***] compound, and Cardax and its licensees shall exclusively purchase
their requirements of Product exclusively from BASF or BASF’s affiliates for such use, including clinical supplies, and for
commercial supplies, for a period of [***] years from the earliest date of commercial introduction of the Product or any compound
that contains the Product, subject to earlier termination under the provisions of the Supply Agreement. The term of the Supply
Agreement shall be subject to extension upon mutual agreement of the Parties.

 

B.                
The purchase price for the Product shall be calculated according to the formula attached hereto as Schedule l.
Payment shall be made within [***] days after the date of invoice without any deductions, except as may be specifically set forth
in the Supply Agreement.

 

C.               
Every [***] months, Cardax will submit to BASF its best estimates of its requirements of Products for the following
[***] months period, providing forecasted volumes split by [***]. Cardax undertakes to purchase and take a minimum amount of Products
of [***]% of the latest forecast for the [***] concerned (“Minimum Amount”). BASF shall make its reasonable best efforts
to meet Cardax’s requirements, provided that BASF shall not be required to supply Product in excess of the latest forecast
by more than [***]% ([***] percent) and BASF shall not be obliged to sell and deliver more than [***] of Products in any [***]
months period. Firm and binding purchase orders for the quantities of Products shall be placed by Cardax in writing at least [***]
working days prior to the desired delivery date.

 

    	13

    	 

    

 

D.               
Products supplied to Cardax shall conform to the specifications to be agreed upon by the Parties and to requirements
of applicable laws and regulations. There is no other warranty or representation of BASF of any kind, especially with regard to
the merchantability, the quality or the fitness of the Products for any use and none shall be implied by law.

 

E.                
Cardax has the duty to examine the Products upon delivery. Unless claims concerning quality or quantity of Product
are raised by Cardax without undue delay within [***] days following receipt of the respective delivery or, in case of hidden defects
that cannot be detected upon reasonable inspection, without undue delay following detection, but no later than [***] days after
delivery, the Products delivered shall be deemed to be accepted. If the Product does not meet the agreed to specifications, Cardax’s
sole remedy and BASF’s sole liability to Cardax is limited to replacement of the nonconforming Product or payment in an amount
not to exceed the purchase price of the specific Product for which damages are claimed, at BASF’s option. Except as provided
in the patent indemnity below and in any indemnity for third party claims (backed by applicable insurance for Cardax) which the
Parties may agree to during Supply Contract negotiations, the liability of either Party to the other Party shall not exceed in
the aggregate [***]. Neither Party will in any event be liable for any loss of profits, loss of use, or any indirect, incidental,
consequential or special damages of any kind whatsoever.

 

F.                
Any and all claims in relation to the delivery of Products, except for claims in case of liability due to death
or personal injury, are subject to a statute of limitation of 2 (two) years.

 

G.               
BASF shall indemnify Cardax for infringement of third party rights to the extent arising from manufacture of
the Product, and Cardax shall indemnify BASF for infringement of third party rights to the extent arising from its further formulation
of the Product as well as the manufacture, storage, sale, distribution and any other use of its finished products or intermediates
containing the Product.

 

    	14

    	 

    

 

H.               
The Supply Agreement shall be governed by and construed in accordance with the substantive laws of the State
of New York, USA, including its provisions of the Uniform Commercial Code, but excluding its conflicts of law principles and excluding
any application of the United Nations Convention on the International Sale of Goods.

 

I.                  
Any dispute arising out of or in connection with the supply of Product that cannot be settled amicably between
the Parties shall be finally resolved as provided in Section 7.2 of the Agreement.

 

J.                 
In the event that BASF cannot supply for any reason, BASF shall [***]. As such [***] solely in order to [***]
for Cardax, [***]. Upon resolution of the supply interruption, all [***] under this paragraph shall [***] and [***], to assure
that Cardax [***]. The following shall be deemed to constitute a failure of supply for this purpose: [***]% of any ordered quantity
is not delivered within [***] business days following the committed delivery dates, or if so delivered, is not in material compliance
with the agreed specifications.

 

K.               
Upon request of Cardax, BASF shall [***], as designated by Cardax, [***], provided that Cardax give BASF sufficient
notice and agrees to [***] (a) before Cardax [***], and (b) at the termination or expiration of the Contract.

 

L.                
The Supply Agreement shall contain other reasonable and customary provisions including, without limitation, provisions
relating to termination, patents and intellectual property, recalls, adverse event reporting, packaging, manner of payment, taxes,
determination of compliance with specifications, delivery procedures, inventory, audits and inspections, supply interruption, force
majeure, Purchaser financial / credit status, indemnification, indemnification procedures, and regulatory requirements and qualifications.

 

M.              
BASF shall be entitled to terminate any supply contract without notice period if BASF in its own discretion decides
to exit the business of manufacture of Astaxanthin. There shall be no compensation rights of Cardax or any third party arising
from such termination. However, upon request of Cardax, BASF shall make available a stock of Product in order to cover Cardax’s
requirements for a transition period not to exceed the greater of: [***].

 

    	15

    	 

    

 

Schedule 1

 

Purchase price index chemicals (PPIC) BASF
AG in [***] is [***].

 

Purchase price in EUR/kg [***] (Incoterms
2000):

 

		·	Volume of [***] but less than [***]:

 

Purchase price according to Appendix I,
Milestone 6

 

		·	Volume of [***] or more:

 

[***]

 

    	16

    	 

    

 

AMENDMENT NO. 1

 

TO

 

JOINT DEVELOPMENT AND SUPPLY AGREEMENT

 

This Amendment No. 1 is entered into effective
on the 15th day of April 2007 (the “Amendment Effective Date”) with respect to the Joint Development and Supply Agreement
entered into effective the 15th day of November, 2006 (the “JDSA”) by and between

 

BASF Aktiengesellschaft, 67056 Ludwigshafen,
Germany acting also on behalf of its Affiliates (hereinafter referred to as “BASF”).

 

and

 

Cardax Pharmaceuticals, Inc., Aiea, Hawaii
96701, USA (hereinafter referred to as “Cardax”).

 

BASF and Cardax are referred to herein
individually as a “Party” and collectively as the “Parties”.

 

Whereas, BASF develops, manufactures, markets
and sells high-value performance chemicals, including fine chemicals for the pharmaceutical industry;

 

Whereas, Cardax is developing proprietary
pharmaceutical compounds;

 

Whereas, the JDSA involves the joint development
and supply of 3S, 3’S Astaxanthin (defined for purposes of this Amendment as the “Original Product” and defined
in the JDSA as the “Product”) which can be used as an intermediate in the manufacture of an active ingredient in pharmaceutical
products or as a nutraceutical product;

 

Whereas, Cardax has developed and owns
an active pharmaceutical ingredient 3S, 3’S Astaxanthin-[***] (the “New Product”) which can be manufactured using
the Original Product as an intermediate;

 

Whereas, pursuant Section 4.1(b) of the
JDSA, Cardax owns the exclusive rights to the formulation and pre-clinical and clinical development of the Original Product as
an intermediate in the manufacture of an active ingredient in pharmaceutical products, including the New Product as such a pharmaceutical
product;

 

Whereas, the Parties desire that Cardax
market or license the New Product as a pharmaceutical product (but not as a nutraceutical product) and that BASF manufacture and
supply the New Product to Cardax and its licensees for this purpose.

 

Now therefore, in consideration of the
above, it is hereby agreed as follows:

 

		1.	BASF agrees to supply the New Product exclusively to Cardax or its licensees under the same terms
and conditions as contained in the JDSA and its Appendix 2 entered into between the Parties for the Original Product, except as
outlined in Section 2 below.

 

    	17

    	 

    

 

		2.	For avoidance of doubt, the Parties acknowledge and agree that the New Product is not a [***].

 

		3.	The milestone plan and feasibility costs for the New Product shall be as set forth in Appendix
1 to this Amendment No. 1. Pricing for [***] (Milestone 4), [***] (Milestone 5), [***], and [***] of the New Product shall be [***].

 

		4.	Subject to the foregoing, the JDSA shall continue in full force and effect in accordance with the
provisions thereof.

 

IN WITNESS WHEREOF, the Parties have executed
this Amendment No. 1 as of the Amendment Effective Date set forth above.

 

Made in two originals in _Ludwigshafen_____________
on April 24, 2007.

 

	Cardax Pharmaceuticals, Inc.	 	BASF Aktiengesellschaft
	 	 	 
	By:	/s/ Thomas H. Goodin	 	By:	[***]
	 	 	 
	Title: VP Preclinical and Clinical 	 	Title: DIRECTOR
	Operations	 	 
	 	 	By: 	[***]
	 	 	Senior Counsel IP

 

    	18

    	 

    

 

APPENDIX I

 

to the

 

Extension of the Joint Development and Supply Agreement

 

between BASF AG and Cardax Pharmaceuticals, Inc.

 

The following project proposal was developed
based on the Cardax information and on BASF process knowledge for 3S,3’S-Astaxanthin-[***].

 

		A.	Start Date

 

It is agreed between Cardax Pharmaceuticals
and BASF AG that the project shall start 15, April 2007.

 

		B.	Milestones

 

It is proposed to conduct the project in
discrete steps (Milestones). Each Milestone will define clear go-no go positions; the completion of the Milestones are essential
for the successful completion of the project.

 

Milestone
1.  

 

[***]

 

Completion Date: [***]

 

Cost: [***] €, payment due within
[***] days after date of invoice from BASF

 

Deliverables: Monthly progress reports

 

Go/No go decision (to proceed to Milestone
2 and in parallel Milestone 3, or to extend Milestone 1, or stop)

 

Milestone
2.  

 

[***]

 

Completion Date: [***]

 

Go/No go decision (to proceed or stop)

 

[***]

 

    	19

    	 

    

 

Milestone
3.  

 

[***]

 

Cost: [***] €, payment due within
[***] days after date of invoice from BASF

 

Completion Date: [***]

 

 

Milestone
4.  

 

[***]

 

Completion Date: [***]

 

Cost and payment schedule: [***]

 

 

Milestone
5.  

 

[***]

 

Completion Date: [***]

 

Cost and payment schedule: [***]

 

		C.	Progress Reports

 

Upon completion of each Milestone BASF
will provide Cardax with a written progress report detailing an updated time and cost estimate for the remaining Milestones based
on the experience made and ask Cardax for clearance to begin the following Milestone. In case unforeseen problems occur during
elaboration of a Milestone, BASF will immediately inform Cardax specifying the effect of such problems on further development and
on cost and time estimates any work requiring additional time of more than [***] to complete or additional cost of more than [***]
% shall be subject to the prior written approval of Cardax.

 

		D.	Payment

 

Payment by Cardax of the costs associated
with each Milestone will be due as defined above. If the project is terminated by Cardax, Cardax will pay to BASF all costs reasonably
incurred until the date of termination.

 

    	20

    	 

    

 

 

 

January 14, 2014

 

BASF SE

Carl-Bosch-Straße 38

67056 Ludwigshafen

Germany

 

We refer to the Joint
Development and Supply Agreement (as amended or supplemented, the “Agreement”) dated with effect on the 15th
day of November, 2006 by and between BASF SE (formerly named BASF Aktiengesellschaft), acting also on behalf of its Affiliates
(collectively, “BASF”) and Cardax Pharmaceuticals, Inc., a Delaware corporation (“Cardax Holdings”).
Cardax Pharma, Inc., a Delaware corporation (“Pharma”), is a subsidiary of Cardax Holdings. On May 31,
2013, Pharma assumed all of the obligations and was assigned all of the rights of Cardax Holdings.

 

By executing and delivering
to us a copy of this letter, you agree that:

 

(1)         all
rights and obligations of Cardax Holdings under the terms of the Agreement have been assigned to, and assumed by, Pharma and, accordingly,
all references to “Cardax” in the Agreement shall be a reference to Pharma; and

 

(2)         BASF
has previously exercised its option in Article 4.4 of the Agreement to convert the non-exclusive license to use Cardax’s
Neutraceutical Interests (as defined in the Agreement) into an exclusive worldwide license in accordance with the terms of the
Agreement.

 

We look forward to continuing
our long-standing relationship with you.

 

	 	Sincerely,	 
	 	 	 
	 	/s/ David G. Watumull	 
	 	David G. Watumull	 
	 	President and CEO	 

 

[continued on the following page]

 

    	 

    	 

    

 

 

BASF SE

Page 2

 

Accepted and agreed as of the date

of this letter first written above.

 

BASF SE

 

	  /s/ Ceransui	 	  /s/ Corinna Klopprogge
	Name: Ceransui	 	Name: Dr. Corinna Klopprogge
	Title:   SVP	 	Title:   Senior Counsel IP
	 	 	Global Intellectual Property

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]